Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11,856.00 GBX | -0.94% | -4.43% | +11.85% |
09-18 | European Equities Close Lower in Wednesday Trading; EU, Euro Area Inflation Declines in August | MT |
09-18 | AstraZeneca Says US FDA Approves Fasenra for Rare Vasculitis Treatment | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Net Income | 1.34B | 3.2B | 112M | 3.29B | 5.96B | |||||
Depreciation & Amortization - CF | 868M | 900M | 959M | 1.1B | 1B | |||||
Amortization of Goodwill and Intangible Assets - (CF) | 1.86B | 1.93B | 3.08B | 4.08B | 3.85B | |||||
Depreciation & Amortization, Total | 2.73B | 2.83B | 4.04B | 5.18B | 4.85B | |||||
Amortization of Deferred Charges, Total - (CF) | 68M | 61M | 63M | 76M | 280M | |||||
(Gain) Loss From Sale Of Asset | -1.22B | -1.06B | -513M | -216M | -292M | |||||
(Gain) Loss on Sale of Investments - (CF) | - | - | -776M | - | - | |||||
Asset Writedown & Restructuring Costs | 966M | 257M | 2.43B | 226M | 456M | |||||
(Income) Loss On Equity Investments - (CF) | 116M | 27M | 64M | 5M | 12M | |||||
Stock-Based Compensation (CF) | -64M | -72M | 45M | 27M | -71M | |||||
Other Operating Activities, Total | -612M | -807M | -1.52B | -2.53B | -1.15B | |||||
Change In Accounts Receivable | -898M | -739M | -961M | -1.35B | -1.42B | |||||
Change In Inventories | -316M | -621M | 1.58B | 3.94B | -669M | |||||
Change In Accounts Payable | 868M | 1.72B | 1.4B | 1.16B | 2.39B | |||||
Cash from Operations | 2.97B | 4.8B | 5.96B | 9.81B | 10.34B | |||||
Capital Expenditure | -979M | -961M | -1.09B | -1.09B | -1.36B | |||||
Sale of Property, Plant, and Equipment | 37M | 106M | 13M | 282M | 132M | |||||
Cash Acquisitions | -709M | -822M | -10.12B | -1.04B | -1.1B | |||||
Sale (Purchase) of Intangible assets | 595M | -694M | -522M | -1.03B | -2.13B | |||||
Investment in Marketable and Equity Securities, Total | 125M | 2B | 605M | -143M | -87M | |||||
Other Investing Activities, Total | 274M | 87M | 54M | 60M | 477M | |||||
Cash from Investing | -657M | -285M | -11.06B | -2.96B | -4.06B | |||||
Short Term Debt Issued, Total | - | 288M | - | 74M | 161M | |||||
Long-Term Debt Issued, Total | 500M | 2.97B | 12.93B | - | 3.82B | |||||
Total Debt Issued | 500M | 3.26B | 12.93B | 74M | 3.98B | |||||
Short Term Debt Repaid, Total | -516M | - | -276M | - | - | |||||
Long-Term Debt Repaid, Total | -1.69B | -1.82B | -5B | -1.52B | -5.21B | |||||
Total Debt Repaid | -2.2B | -1.82B | -5.28B | -1.52B | -5.21B | |||||
Issuance of Common Stock | 3.52B | 30M | 29M | 29M | 33M | |||||
Common Dividends Paid | -3.59B | -3.57B | -3.86B | -4.36B | -4.48B | |||||
Common & Preferred Stock Dividends Paid | -3.59B | -3.57B | -3.86B | -4.36B | -4.48B | |||||
Other Financing Activities, Total | 4M | -101M | -178M | -1.05B | -886M | |||||
Cash from Financing | -1.76B | -2.2B | 3.65B | -6.82B | -6.57B | |||||
Foreign Exchange Rate Adjustments | 5M | 12M | -62M | -80M | -60M | |||||
Net Change in Cash | 552M | 2.32B | -1.51B | -55M | -346M | |||||
Supplemental Items | ||||||||||
Cash Interest Paid | 774M | 733M | 721M | 849M | 1.08B | |||||
Cash Income Tax Paid (Refund) | 1.12B | 1.56B | 1.74B | 1.62B | 2.37B | |||||
Levered Free Cash Flow | 6.26B | 3.3B | -896M | 12.36B | 9.5B | |||||
Unlevered Free Cash Flow | 6.75B | 3.76B | -412M | 12.94B | 10.06B | |||||
Change In Net Working Capital | -2.13B | 347M | 6.52B | -3.59B | -1.52B | |||||
Net Debt Issued / Repaid | -1.7B | 1.44B | 7.65B | -1.44B | -1.23B |